» Articles » PMID: 38313569

Triamcinolone Acetonide Injections in Nail Psoriasis: A Pragmatic Analysis

Overview
Specialty Dermatology
Date 2024 Feb 5
PMID 38313569
Authors
Affiliations
Soon will be listed here.
Abstract

Introduction: Treatment of nail psoriasis is challenging. Systemic therapies may be difficult to justify, while topical therapies may be sup-optimal. Triamcinolone acetonide (TA) injections are recommended as first-line therapy in cases with less than 3 nails involved; however, limited studies are available. This study was conducted to evaluate the reduction in NAPSI (Nail Psoriasis Severity Index) with TA injections in patients with isolated nail psoriasis.

Methods: A retrospective case record analysis of efficacy and safety of TA (5 mg/mL) nail injections (4-weekly for fingernails, 8-weekly for toenails) was done in 10 patients. NAPSI was evaluated at each visit and treatment endpoint (75% reduction or 10 injections, whichever was earlier). Dropouts and adverse effects were recorded.

Results: Among 10 patients (94 involved nails, 61 fingernails, and 33 toenails), 3 patients (30%) dropped out (2, 4, and 5 sessions, respectively), citing procedural pain. Three patients achieved NAPSI-75 (3, 6, and 7 sessions, respectively). Baseline mean NAPSI of 5.03 (4.63 fingernails and 5.78 toenails) dropped to 3.67 (3.13 fingernails and 4.42 toenails) by the 5th injection; and 2.35 (2.13 fingernails and 2.59 toenails) by the 10th injection. Adverse effects included pain (30%), subungual haematoma (1.7%), and proximal nail fold hypopigmentation with mild atrophy (1.1%).

Conclusions: TA (5 mg/mL) injections are effective in nail psoriasis and associated with minimal adverse effects.

References
1.
Saleem K, Azim W . Treatment of nail psoriasis with a modified regimen of steroid injections. J Coll Physicians Surg Pak. 2008; 18(2):78-81. DOI: 02.2008/JCPSP.7881. View

2.
Ortonne J, Baran R, Corvest M, Schmitt C, Voisard J, Taieb C . Development and validation of nail psoriasis quality of life scale (NPQ10). J Eur Acad Dermatol Venereol. 2010; 24(1):22-7. DOI: 10.1111/j.1468-3083.2009.03344.x. View

3.
Rich P, Griffiths C, Reich K, Nestle F, Scher R, Li S . Baseline nail disease in patients with moderate to severe psoriasis and response to treatment with infliximab during 1 year. J Am Acad Dermatol. 2007; 58(2):224-31. DOI: 10.1016/j.jaad.2007.07.042. View

4.
Starace M, Alessandrini A, Iorizzo M, DAltobrando A, Ferrari T, Bruni F . A pilot study of intralesional methotrexate injections versus triamcinolone acetonide in patients affected by nail matrix psoriasis. Clin Exp Dermatol. 2022; 47(6):1165-1168. PMC: 9303444. DOI: 10.1111/ced.15110. View

5.
Rigopoulos D, Baran R, Chiheb S, Daniel 3rd C, Di Chiacchio N, Gregoriou S . Recommendations for the definition, evaluation, and treatment of nail psoriasis in adult patients with no or mild skin psoriasis: A dermatologist and nail expert group consensus. J Am Acad Dermatol. 2019; 81(1):228-240. DOI: 10.1016/j.jaad.2019.01.072. View